tetano
Editor, Senior Moderator
J Gen Virol
. 2023 Feb;104(2).
doi: 10.1099/jgv.0.001821.
A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model
Kevin Purves[SUP] 1 [/SUP], Ruth Haverty[SUP] 1 [/SUP], Tiina O'Neill[SUP] 2 [/SUP], David Folan[SUP] 3 [/SUP], Sophie O'Reilly[SUP] 4 [/SUP], Alan W Baird[SUP] 1 2 [/SUP], Dimitri Scholz[SUP] 2 [/SUP], Patrick W Mallon[SUP] 4 5 [/SUP], Virginie Gautier[SUP] 4 [/SUP], Michael Folan[SUP] 3 [/SUP], Nicola F Fletcher[SUP] 1 2 [/SUP]
Affiliations
Abstract
A novel proprietary formulation, ViruSAL, has previously been demonstrated to inhibit diverse enveloped viral infections in vitro and in vivo. We evaluated the ability of ViruSAL to inhibit SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infectivity, using physiologically relevant models of the human bronchial epithelium, to model early infection of the upper respiratory tract. ViruSAL potently inhibited SARS-CoV-2 infection of human bronchial epithelial cells cultured as an air-liquid interface (ALI) model, in a concentration- and time-dependent manner. Viral infection was completely inhibited when ViruSAL was added to bronchial airway models prior to infection. Importantly, ViruSAL also inhibited viral infection when added to ALI models post-infection. No evidence of cellular toxicity was detected in ViruSAL-treated cells at concentrations that completely abrogated viral infectivity. Moreover, intranasal instillation of ViruSAL to a rat model did not result in any toxicity or pathological changes. Together these findings highlight the potential for ViruSAL as a novel and potent antiviral for use within clinical and prophylactic settings.
Keywords: antiviral; caprylate; caprylic acid; coronavirus; enveloped virus; viral envelope.
. 2023 Feb;104(2).
doi: 10.1099/jgv.0.001821.
A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model
Kevin Purves[SUP] 1 [/SUP], Ruth Haverty[SUP] 1 [/SUP], Tiina O'Neill[SUP] 2 [/SUP], David Folan[SUP] 3 [/SUP], Sophie O'Reilly[SUP] 4 [/SUP], Alan W Baird[SUP] 1 2 [/SUP], Dimitri Scholz[SUP] 2 [/SUP], Patrick W Mallon[SUP] 4 5 [/SUP], Virginie Gautier[SUP] 4 [/SUP], Michael Folan[SUP] 3 [/SUP], Nicola F Fletcher[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36787173
- DOI: 10.1099/jgv.0.001821
Abstract
A novel proprietary formulation, ViruSAL, has previously been demonstrated to inhibit diverse enveloped viral infections in vitro and in vivo. We evaluated the ability of ViruSAL to inhibit SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infectivity, using physiologically relevant models of the human bronchial epithelium, to model early infection of the upper respiratory tract. ViruSAL potently inhibited SARS-CoV-2 infection of human bronchial epithelial cells cultured as an air-liquid interface (ALI) model, in a concentration- and time-dependent manner. Viral infection was completely inhibited when ViruSAL was added to bronchial airway models prior to infection. Importantly, ViruSAL also inhibited viral infection when added to ALI models post-infection. No evidence of cellular toxicity was detected in ViruSAL-treated cells at concentrations that completely abrogated viral infectivity. Moreover, intranasal instillation of ViruSAL to a rat model did not result in any toxicity or pathological changes. Together these findings highlight the potential for ViruSAL as a novel and potent antiviral for use within clinical and prophylactic settings.
Keywords: antiviral; caprylate; caprylic acid; coronavirus; enveloped virus; viral envelope.